{"id":"NCT00831753","sponsor":"Sanofi Pasteur, a Sanofi Company","briefTitle":"Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Infanrix®Hexa in Healthy Peruvian Infants","officialTitle":"Immunogenicity Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine in Comparison to Infanrix®Hexa, at 2-4-6 Months of Age in Healthy Peruvian Infants","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-05","primaryCompletion":"2009-05","completion":"2009-11","firstPosted":"2009-01-29","resultsPosted":"2014-04-02","lastUpdate":"2016-05-13"},"enrollment":263,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"PREVENTION"},"conditions":["Diphtheria","Tetanus","Pertussis","Haemophilus Influenzae Type b","Hepatitis B"],"interventions":[{"type":"BIOLOGICAL","name":"DTaP IPV HB PRP~T vaccine","otherNames":[]},{"type":"BIOLOGICAL","name":"DTaP-HB-IPV and Haemophilus influenzae type b","otherNames":["Infanrix® Hexa"]}],"arms":[{"label":"Group 1","type":"EXPERIMENTAL"},{"label":"Group 2","type":"ACTIVE_COMPARATOR"}],"summary":"The study aims to confirm that, in Peruvian infants, the investigational DTaP-IPV Hep B-PRP\\~T vaccine has immunological and safety profiles that are comparable to those of the control vaccine that is already marketed (Infanrix®Hexa)\n\nPrimary Objective:\n\nTo demonstrate that the hexavalent DTaP-IPV-Hep B-PRP\\~T combined vaccine induces an immune response that is at least as good as the response following Infanrix®Hexa in terms of seroprotection rates to HB, one month after a three-dose primary series (2, 4 and 6 months)\n\nSecondary Objectives:\n\n* To describe in each group the immunogenicity to vaccine components (for DTaP-IPV-Hep B-PRP\\~T and Infanrix®Hexa) one month after the third dose of the primary series.\n* To assess the overall safety in each group one month after each dose of the primary series and through the entire study.","primaryOutcome":{"measure":"Number of Participants Achieving Seroprotection for Anti Hep-B After a Primary Series of Vaccination With Either DTaP-IPV-Hep B-PRP~T or Infanrix Hexa™","timeFrame":"Day 150 (1 month after dose 3)","effectByArm":[{"arm":"DTaP-IPV-Hep B-PRP~T Group","deltaMin":131,"sd":null},{"arm":"Infanrix Hexa™ Group","deltaMin":130,"sd":null}],"pValues":[]},"eligibility":{"minAge":"50 Days","sex":"ALL","healthyVolunteers":true,"inclusionCount":6,"exclusionCount":14},"locations":{"siteCount":1,"countries":["Peru"]},"refs":{"pmids":[],"seeAlso":["http://www.sanofipasteur.com"]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":132},"commonTop":["Injection Site Pain","Irritability","Crying","Somnolence","Injection Site Erythema"]}}